Primary Results of Phase 2 FOENIX-CCA2: the Irreversible FGFR1–4 Inhibitor Futibatinib in Intrahepatic Cholangiocarcinoma With FGFR2 Fusions/Rearrangements
Lipika Goyal,1 Funda Meric-Bernstam,2 Antoine Hollebecque,3 Chigusa Morizane,4 Juan W. Valle,5 Thomas B. Karasic,6 Thomas A. Abrams,7 Robin Kate Kelley,8 Philippe Cassier,9 Junji Furuse,10 Heinz-Josef Klümpen,11 Heung-Moon Chang,12 Li-Tzong Chen,13 Yoshito Komatsu,14 Kunihiro Masuda,15 Daniel Ahn,16 Yaohua He,17 Nital Soni,17 Karim A. Benhadji,17 John A. Bridgewater18
1Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA; 2University of Texas MD Anderson Cancer Center, Houston, TX, USA; 3Drug Development, Institut Gustave Roussy, Villejuif, France; 4National Cancer Center Hospital, Tokyo, Japan; 5University of Manchester and The Christie NHS Foundation Trust, Manchester, UK; 6Hospital of the University of Pennsylvania, Philadelphia, PA, USA; 7Dana-Farber Cancer Institute, Boston, MA, USA; 8University of California, San Francisco, CA, USA; 9Centre Léon-Bérard, Lyon, France; 10Kyorin University, Faculty of Medicine, Tokyo, Japan; 11Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands; 12Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; 13National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan; 14Division of Cancer Chemotherapy, Hokkaido University Hospital Cancer Center, Hokkaido, Japan; 15Tohoku University Graduate School of Medicine, Seiryo-machi, Aoba-ku, Sendai, Miyagi, Japan; 16Mayo Clinic, Phoenix, AZ, USA; 17Taiho Oncology, Inc., Princeton, NJ, USA; 18UCL Cancer Institute, London, UK